The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Apollo: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2, or PALB2 mutation—ECOG-ACRIN EA2192.
 
Kim Anna Reiss
Honoraria - MJH Life Sciences
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Carisma Therapeutics; Foundation Medicine
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology; GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Tesaro (Inst)
 
Sung Chul Hong
No Relationships to Disclose
 
Anup Kasi
Consulting or Advisory Role - Ipsen
Research Funding - Ability Pharma (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Cardiff Oncology (Inst); Cend Therapeutics (Inst); FibroGen (Inst); Geistlich Pharma (Inst); Novocure (Inst); Rafael Pharmaceuticals (Inst); TESARO (Inst)
 
Eileen Mary O'Reilly
Consulting or Advisory Role - AstraZeneca; Autem Medical (I); Boehringer Ingelheim; Eisai (I); Exelixis (I); Genentech/Roche (I); Helio Health (I); Incyte (I); Ipsen; Merck; Novartis; QED Therapeutics (I); Yiviva (I); Yiviva (I)
Research Funding - Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Roche (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
Shishir K. Maithel
Consulting or Advisory Role - AstraZeneca
Research Funding - Celgene
 
Xin Yao
Honoraria - Research to Practice; Targeted Oncology; Xcenda
 
Stanley R. Hamilton
Research Funding - Intima; Minerva Biotechnologies
 
Ben Boursi
No Relationships to Disclose
 
Michael J. Pishvaian
Stock and Other Ownership Interests - Perthera; Targeting Resistance in Cancer Cooperative; Tumor Board Tuesday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; IDEAYA Biosciences; Merck; Merus; Novartis; Pfizer; Pionyr; Seagen; TriSalus Life Sciences
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); RenovoRx (Inst); Repare Therapeutics (Inst); Seagen (Inst); Takeda (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Perthera patient matching algorithm; Use patent for veliparib and FOLFOX
Travel, Accommodations, Expenses - Astellas Pharma
 
Samuel J Klempner
Stock and Other Ownership Interests - Nuvalent, Inc.; TP Therapeutics
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Coherus Biosciences; Daiichi Sankyo/UCB Japan; Exact Sciences; Merck; Mersana; Novartis; Sanofi/Aventis; SERVIER
Research Funding - BeiGene (Inst); Leap Therapeutics (Inst); Silverback Therapeutics (Inst)
Other Relationship - Clinical Care Options; NCCN; Research to Practice
 
Susan M. Domchek
Honoraria - AstraZeneca; GlaxoSmithKline
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst)
 
Paul J. Catalano
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Regeneron (Inst)
 
E. Gabriela Chiorean
Consulting or Advisory Role - Astellas Pharma; Axiom Healthcare Strategies; Bayer; Bristol-Myers Squibb/Celgene; Cardiff Oncology; Foundation Medicine; G1 Therapeutics; IgM Biosciences; Ipsen; Merck; Merus; Novartis; Pfizer; Stemline Therapeutics
Research Funding - AADi (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Erasca, Inc; FibroGen (Inst); Gilead/Forty Seven; Lonza (Inst); Merck (Inst); Novartis; Rafael Pharmaceuticals (Inst); Roche (Inst); Stemline Therapeutics (Inst)
Travel, Accommodations, Expenses - G1 Therapeutics
 
Philip Agop Philip
Honoraria - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb/Medarex; Celgene; Daiichi Sankyo/Astra Zeneca; Guardant Health; Guardant Health; incyte; Ipsen; Merck; Rafael Pharmaceuticals; SynCoreBio; TriSalus Life Sciences
Consulting or Advisory Role - Celgene; Daiichi Sankyo; Ipsen; Merck; SynCoreBio; Taiho Pharmaceutical; TriSalus Life Sciences
Speakers' Bureau - Bayer; Bristol-Myers Squibb/Medarex; Celgene; Incyte; Ipsen; Novartis
Research Funding - Advanced Accelerator Applications (Inst); ASLAN Pharmaceuticals (Inst); Bayer (Inst); boston biomedical (Inst); Caris Life Sciences (Inst); Caris Life Sciences (Inst); Genentech (Inst); halozyme (Inst); Immunomedics (Inst); incyte (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); merus (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TYME (Inst); tyme (Inst)
Travel, Accommodations, Expenses - Abbvie; celgene; Rafael Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - Caris MPI; Rafael Pharmaceuticals
 
Peter J. O'Dwyer
Research Funding - Amgen (Inst); Array BioPharma (Inst); BBI Healthcare (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Lilly/ImClone (Inst); Minneamrita Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); syndax (Inst); Taiho Pharmaceutical (Inst)
Expert Testimony - Dai-ichi Sankyo